Enobia Pharma Announces the Appointment of Dr. Hal Landy as VP Medical Affairs, Chief Medical Officer
Enobia Pharma, announced that it has appointed Hal Landy, MD as the Company's VP Medical Affairs & Chief Medical Officer.
Dr. Landy, has 15 years of senior management experience in the biopharmaceutical industry. From 2003 through 2007, Dr. Landy served as Vice-President Clinical Development with Repligen Corporation where he oversaw programs in autism, neuropsychiatric indications, immunological diseases, gastroenterology and imaging.
Prior to joining Repligen, Dr. Landy was Vice-President Clinical Research of Genzyme. He was the medical lead on an extensive and ultimately successful program in Pompe disease. Before that, Dr. Landy served in various capacities at Serono, both in the US and Geneva, where he oversaw successful programs in growth-related disorders and worked in AIDS-wasting and metabolism.
Dr. Landy received his MD from the College of Physicians and Surgeons, Columbia University in 1981. He subsequently trained in Pediatrics and Adolescent Medicine at Massachusetts General Hospital and Children's Hospital, Boston, and was Board certified in Pediatrics in 1987 and in Pediatric Endocrinology in 1989. He was Assistant in Medicine at Children's Hospital, Boston and Instructor in Pediatrics, Harvard Medical School from 1989 - 1996.
Other news from the department people
